The U.S. Army awarded Olin a $788.4 million contract to supply small-arms ammunition through September 2031, a deal that adds roughly 2.2 percent to the company’s annual revenue base. For a chemical maker with a $6.8 billion top line in 2025, the incremental $157.7 million per year is measurable but not transformative.
The contract math
Spread over five years, the award translates to about $157.7 million of additional revenue annually. That figure represents a 2.2 percent lift on 2025 sales of $6.8 billion. The Pentagon’s fiscal-year-end rush typically produces a cluster of awards in late September; this one arrived early.
Cash flow versus earnings
Olin posted roughly $100 million of positive free cash flow over the trailing twelve months despite reporting a net loss. Analysts surveyed by S&P Global project that figure to reach nearly $180 million by the end of 2026 and $300 million in 2027. At a market value near $2 billion and net debt exceeding $3.2 billion, the stock trades at less than 29 times trailing free cash flow.
Valuation context
The multiple is not obviously cheap, but the expected growth trajectory, accelerated by steady defense spending, makes the arithmetic more compelling. The Army contract alone does not move the needle, yet it reinforces a revenue stream that is already benefiting from replenishment demand.
The contrarian view
The Motley Fool’s Stock Advisor service recently published its ten best ideas for new money; Olin was not among them. The list’s historical average return is cited at 940 percent versus 211 percent for the S&P 500, though past performance of a newsletter portfolio is not a benchmark for a single industrial name.
What to watch
Next quarter’s cash flow conversion and any follow-on ammunition orders will matter more than the headline award. The fiscal 2027 defense budget cycle, now entering its formulation phase, will signal whether the current replenishment pace sustains.